Name:
110401_Cox_Rational-Use-of-Mox ...
Size:
40.05Kb
Format:
PDF
Description:
Main Article
Affiliation
Burnet Institute, Melbourne, Australia; Médecins Sans Frontières, Johannesburg, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Harvard Medical School, Boston, USA; Partners in Health, Boston, USA; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, SwitzerlandIssue Date
2011-04-01Submitted date
2011-04-29
Metadata
Show full item recordJournal
Lancet Infectious DiseasesPubMed ID
21453864Additional Links
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70036-6/fulltext?_eventId=loginType
ArticleLanguage
enISSN
1474-4457ae974a485f413a2113503eed53cd6c53
10.1016/S1473-3099(11)70036-6
Scopus Count
Collections
Related articles
- Moxifloxacin for tuberculosis.
- Authors: Singh KP, Brown M, Murphy ME, Gillespie SH
- Issue date: 2012 Mar
- Moxifloxacin for tuberculosis.
- Authors: Mendel C, Springsklee M
- Issue date: 2012 Mar
- Moxifloxacin.
- Issue date: 2008 Mar
- Doctors report breakthrough antibiotic treatment for TB.
- Issue date: 2007 Nov
- New drug combination for TB is tested in unique trial.
- Authors: Kmietowicz Z
- Issue date: 2012 Jul 25